Close
Blog & Resources Camargo Blog January 9th, 2012

2011 505(b)(2) Approvals Now Exceed 505(b)(1) NDA Approvals

What a year for 505(b)(2) drug development! In 2011 FDA approved 44 505(b)(2) NDA submissions. Various authors have reported that FDA approved 34 or 35 drugs in 2011 (505(b)(1) NDA + BLA). I had speculated a couple of years ago that perhaps 80% of new drugs approved in 2012 would be 505(b)(2)’s, based on botha declining new drug approval and an increase in 505(b)(2)’s. In fact, the new drug approvals increased from 2010.

In 2011, FDA approved 33 new formulations, 1 New Molecular Entity, 7 new combinations and 3 formerly unapproved drugs. I have listed the approvals by these categories in my annual scorecard.

Of the 33 pharmaceutical companies obtaining approvals, Hospira was the most active 505(b)(2) sponsor in 2011 with 5 approvals, followed by Sandoz with 4 approvals. Abbott, Cypress, Prostrakan each had 2 approvals. All of the other sponsors had one approval.

The careful observer will note that apparently the same product was approved for more than one sponsor. It turns out that these products are injectables and there are differences in excipients that ensure that they are not the “same” product.



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
2505 Meridian Parkway
Suite 150
Durham NC, 27713
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights